UT SOUTHWESTERN MEDICAL CENTER IMAGE: A NEW TYPE OF CAR T-CELL THERAPY MORE THAN TRIPLES THE EXPECTED LENGTH OF REMISSION FOR MULTIPLE MYELOMA PATIENTS WHO HAVE RELAPSED SEVERAL TIMES, ACCORDING TO AN INTERNATIONAL CLINICAL TRIAL WITH UT SOUTHWESTERN AS THE LEAD ENROLLING SITE. CREDIT: UT SOUTHWESTERN MEDICAL CENTER DALLAS – March 8, 2021 – A...
by Dana-Farber Cancer Institute Nikhil Munshi, MD Credit: Dana-Farber Cancer Institute In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found. In a study posted online today by the New England Journal of...
by Queen Mary, University of London A pancreatic islet from a mouse in a typical position, close to a blood vessel; insulin in red, nuclei in blue. Credit: Generated in the Solimena lab, Paul Langerhans Institute Dresden Researchers from Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the...
Some cancer cells refuse to die, even in the face of powerful cellular immunotherapies like CAR T cell therapy, and new research from the Abramson Cancer Center of the University of Pennsylvania is shedding light on why. In a new study, researchers describe how a death receptor pathway in the cancer cell itself plays a...
A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment with axi-cel (marketed as Yescarta). The study, named ZUMA-1, also reported measurable responses in 82 percent of patients and complete responses in...
The science behind harnessing the immune system to fight cancer is complicated, but a University of Rochester Medical Center laboratory discovered a simple, practical way to use light and optics to steer killer immune cells toward tumors. In a study published by the online journal Nature Communications, lead author Minsoo Kim, Ph.D., a UR professor of Microbiology and Immunology and a Wilmot Cancer...
Procedure is administered during three or four hospital outpatient appointments It has shown particular promise for leukaemia and blood cancers A revolutionary cancer treatment that alters the body’s cells so they attack tumours has offered hope of a cure. The procedure is administered during three or four hospital outpatient appointments which last up to four...
Multiple Myeloma The United States has more than 30,000 cases of multiple myeloma occurring each year. The condition affects the plasma cells that produce antibodies that fight infection. Between 60,000 and 70,000 American currently have the disease. Only about half of these patients are expected to live five years after their diagnosis. Now, a gene-based...
Glioblastoma is the most common brain tumor in humans and also one of the most difficult cancers to treat; patients with this type of cancer only survive about one year from time of diagnosis. Researchers at Baylor College of Medicine, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor, Texas...
A patient has been successful treated from recurrent multifocal glioblastoma through the means of CAR-T therapy. The method involves a specific kind of immunotherapy which targets cells where the IL13Rα2 antigen is present. The antigen is very common when it comes to brain cancer. Published in the New England Journal of Medicine on Dec. 29, the study...
